Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Saudi International Ex...Saudi International Expo
Not Confirmed
Not Confirmed
28-30 October, 2024
SupplySide West 2024SupplySide West 2024
Not Confirmed
Not Confirmed
28 October-01 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Saudi International Ex...Saudi International Expo
Industry Trade Show
Not Confirmed
28-30 October, 2024
SupplySide West 2024SupplySide West 2024
Industry Trade Show
Not Confirmed
28 October-01 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/due-to-its-20-year-mastery-in-micronization-inke-has-emerged-a-cornerstone-in-treating-global-respiratory-diseases
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/dmf-filings-hit-all-time-high-in-q3-2024-china-tops-list-with-58-increase-in-type-ii-submissions
30 Sep 2024
// BUSINESSWIRE
06 Sep 2024
// REUTERS
https://www.reuters.com/legal/government/purdue-pharma-gets-extension-sackler-settlement-talks-2024-09-05/
09 Aug 2024
// FDA
https://www.fda.gov/news-events/press-announcements/fda-approves-first-nalmefene-hydrochloride-auto-injector-reverse-opioid-overdose
07 Aug 2024
// BUSINESSWIRE
09 Jul 2024
// BUSINESSWIRE
08 Jul 2024
// REUTERS
https://www.reuters.com/legal/purdue-creditors-seek-approval-sue-sackler-family-members-2024-07-08/
Details:
Nalmefene Hydrochloride Injection is indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids.
Lead Product(s): Nalmefene Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Zurnai
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2024
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Study on Nalmefene Injection For Opioid Overdose in ERs Concludes
Details : Nalmefene Hydrochloride Injection is indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids.
Brand Name : Zurnai
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 30, 2024
Details:
Zurnai (nalmefene hydrochloride) Injection is indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids.
Lead Product(s): Nalmefene Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Zurnai
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 07, 2024
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves Zurnai™ Auto-Injector for Opioid Overdose Treatment in Adults and Children
Details : Zurnai (nalmefene hydrochloride) Injection is indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids.
Brand Name : Zurnai
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 07, 2024
Details:
Nalmefene Hydrochloride Injection is indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids.
Lead Product(s): Nalmefene Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Zurnai
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 07, 2024
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves First Nalmefene Hydrochloride Auto-Injector to Reverse Opioid Overdose
Details : Nalmefene Hydrochloride Injection is indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids.
Brand Name : Zurnai
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 07, 2024
Details:
The agreement provides low-cost buprenorphine and naloxone tablets to correctional facilities for opioid use disorder treatment.
Lead Product(s): Buprenorphine Hydrochloride,Naloxone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Suboxone-Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: MMCAP Infuse
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 06, 2024
Lead Product(s) : Buprenorphine Hydrochloride,Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : MMCAP Infuse
Deal Size : Undisclosed
Deal Type : Agreement
Purdue Pharma Enters Agreement for Low-Cost Opioid Use Disorder Treatment in Prisons
Details : The agreement provides low-cost buprenorphine and naloxone tablets to correctional facilities for opioid use disorder treatment.
Brand Name : Suboxone-Generic
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 06, 2024
Details:
The grant will be used for the evaluation of nalmefene hydrochloride (HCl) injection, an opioid antagonist indicated for the complete or partial reversal of opioid drug effects.
Lead Product(s): Nalmefene Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Nalmefene HCl-Generic
Study Phase: ApprovedProduct Type: Small molecule
Recipient: The University of New Mexico
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing March 27, 2024
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Recipient : The University of New Mexico
Deal Size : Undisclosed
Deal Type : Financing
Purdue Grants Funding for Research on Opioid Overdose Reversal with Nalmefene Injection
Details : The grant will be used for the evaluation of nalmefene hydrochloride (HCl) injection, an opioid antagonist indicated for the complete or partial reversal of opioid drug effects.
Brand Name : Nalmefene HCl-Generic
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 27, 2024
Details:
The proceeds will be used to fund commercial readiness for HRT’s low-cost over-the-counter (OTC) intranasal naloxone spray, tradename RiVive. Naloxone is an opioid antagonist rescue medication used to reverse the effects of a life-threatening opioid overdose.
Lead Product(s): Naloxone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Rivive
Study Phase: Phase IIIProduct Type: Small molecule
Recipient: Harm Reduction Therapeutics
Deal Size: $29.9 million Upfront Cash: Undisclosed
Deal Type: Financing March 21, 2023
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Recipient : Harm Reduction Therapeutics
Deal Size : $29.9 million
Deal Type : Financing
Details : The proceeds will be used to fund commercial readiness for HRT’s low-cost over-the-counter (OTC) intranasal naloxone spray, tradename RiVive. Naloxone is an opioid antagonist rescue medication used to reverse the effects of a life-threatening opioid ov...
Brand Name : Rivive
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 21, 2023
Details:
Nalmefene is an opioid antagonist indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids, and in the management of known or suspected opioid overdose.
Lead Product(s): Nalmefene Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Nalmefene Hydrochloride- Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Nalmefene is an opioid antagonist indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids, and in the management of known or suspected opioid overdose.
Brand Name : Nalmefene Hydrochloride- Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 21, 2022
Details:
The additional funding approved today will help HRT continue its work toward making OTC naloxone nasal spray available to the public. HRT plans to file a New Drug Application for naloxone nasal spray with FDA in 2022.
Lead Product(s): Naloxone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Revive
Study Phase: Phase IProduct Type: Small molecule
Recipient: Harm Reduction Therapeutics
Deal Size: $17.5 million Upfront Cash: Undisclosed
Deal Type: Financing March 23, 2022
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Recipient : Harm Reduction Therapeutics
Deal Size : $17.5 million
Deal Type : Financing
Details : The additional funding approved today will help HRT continue its work toward making OTC naloxone nasal spray available to the public. HRT plans to file a New Drug Application for naloxone nasal spray with FDA in 2022.
Brand Name : Revive
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 23, 2022
Details:
FDA recently approved ANDA for nalmefene hydrochloride Injection, an opioid antagonist indicated for reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids, and in management of known or suspected opioid overdose.
Lead Product(s): Nalmefene Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Nalmefene Hydrochloride-Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2022
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : FDA recently approved ANDA for nalmefene hydrochloride Injection, an opioid antagonist indicated for reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids, and in management of known or suspecte...
Brand Name : Nalmefene Hydrochloride-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 17, 2022
Details:
FDA has approved ANDA for Nalmefene hydrochloride injection, an opioid antagonist indicated for the complete or partial reversal of opioid drug effects, induced by either natural or synthetic opioids, and in management of known suspected opioid overdose.
Lead Product(s): Nalmefene Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Nalmefene Hydrochloride-Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2022
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : FDA has approved ANDA for Nalmefene hydrochloride injection, an opioid antagonist indicated for the complete or partial reversal of opioid drug effects, induced by either natural or synthetic opioids, and in management of known suspected opioid overdose.
Brand Name : Nalmefene Hydrochloride-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 23, 2022
Inspections and registrations
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?